Investigational Drug Information for Ipatasertib
✉ Email this page to a colleague
What is the drug development status for Ipatasertib?
Ipatasertib is an investigational drug.
There have been 56 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2023.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).
There are one hundred and twenty-four US patents protecting this investigational drug and zero international patents.
Summary for Ipatasertib
| US Patents | 124 |
| International Patents | 1,598 |
| US Patent Applications | 435 |
| WIPO Patent Applications | 341 |
| Japanese Patent Applications | 129 |
| Clinical Trial Progress | Phase 2 (2023-06-01) |
| Vendors | 49 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | Hoffmann-La Roche | Phase 4 |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Study of Chemotherapy Plus Ipatasertib in Participants With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | ⤷ Sign Up | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Sign Up |
| Ipatasertib | ⤷ Sign Up | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Sign Up |
| Ipatasertib | ⤷ Sign Up | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Sign Up |
| Ipatasertib | ⤷ Sign Up | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Ipatasertib | ⤷ Sign Up | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | Argentina | AR107432 | 2036-01-11 | ⤷ Sign Up |
| Ipatasertib | Australia | AU2017207268 | 2036-01-11 | ⤷ Sign Up |
| Ipatasertib | Australia | AU2019203280 | 2036-01-11 | ⤷ Sign Up |
| Ipatasertib | Australia | AU2021201018 | 2036-01-11 | ⤷ Sign Up |
| Ipatasertib | Brazil | BR112018014015 | 2036-01-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
